{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:17:27Z","timestamp":1790702247244,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals using onabotulinumtoxinA as a preventive migraine treatment often use acute treatments for breakthrough attacks. Data on real-world effectiveness of the small-molecule calcitonin gene\u2013related peptide (CGRP) receptor antagonist ubrogepant in combination with onabotulinumtoxinA are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>COURAGE, a prospective, multiple attack, observational study, evaluated the real-world effectiveness of ubrogepant (50 or 100\u00a0mg) for acute treatment of migraine in people receiving onabotulinumtoxinA, an anti-CGRP monoclonal antibody (mAb), or both. This analysis focused only on onabotulinumtoxinA users. The Migraine Buddy app was used to identify eligible participants and track response to treated attacks. For each ubrogepant-treated attack, meaningful pain relief (MPR) and return to normal function (RNF) at 2 and 4\u00a0h post-dose over 30\u00a0days was assessed. MPR was defined as a level of relief that is meaningful to the participant, usually occurring before the pain is all gone. After 30\u00a0days, satisfaction was reported on a 7-point scale and overall acute treatment optimization was evaluated using the migraine Treatment Optimization Questionnaire-4 (mTOQ-4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis included 122 participants who received ubrogepant and onabotulinumtoxinA and reported on 599 ubrogepant-treated attacks. Following the first ubrogepant-treated attack, MPR was achieved in 53.3% of participants 2\u00a0h post-dose and in 76.2% of participants 4\u00a0h post-dose. RNF was achieved in 25.4% of participants 2\u00a0h post-dose and in 45.9% of participants 4\u00a0h post-dose. MPR and RNF results were similar across up to 10 ubrogepant-treated attacks. After 30\u00a0days, satisfaction with ubrogepant in combination with onabotulinumtoxinA was reported by 69.8% of participants and acute treatment optimization (defined as mTOQ-4 score\u2009\u2265\u20094) was achieved in 77.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this prospective real-world effectiveness study, ubrogepant treatment in onabotulinumtoxinA users with self-identified migraine was associated with high rates of MPR and RNF at 2 and 4\u00a0h as well as satisfaction and acute treatment optimization. Although the lack of a contemporaneous control group limits causal inference, these findings demonstrate the feasibility of using a novel, app-based design to evaluate the real-world effectiveness and satisfaction of treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01622-0","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T03:01:28Z","timestamp":1691031688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study"],"prefix":"10.1186","volume":"24","author":[{"given":"Aubrey","family":"Manack Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Engstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai D.","family":"Ayasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Contreras-De Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"1622_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695\u2013706","journal-title":"N Engl J Med"},{"key":"1622_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V et al (2019) Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. J Headache Pain 20:57","journal-title":"J Headache Pain"},{"key":"1622_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/head.14244","volume":"62","author":"J Ailani","year":"2022","unstructured":"Ailani J, Blumenfeld AM (2022) Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache 62:106\u2013108","journal-title":"Headache"},{"key":"1622_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/0333102420970507","volume":"41","author":"A Melo-Carrillo","year":"2021","unstructured":"Melo-Carrillo A, Strassman AM, Schain AJ, Adams AM, Brin MF, Burstein R (2021) Combined onabotulinumtoxinA\/atogepant treatment blocks activation\/sensitization of high-threshold and wide-dynamic range neurons. Cephalalgia 41:17\u201332","journal-title":"Cephalalgia"},{"key":"1622_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"60","author":"R Burstein","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF (2020) Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache 60:1259\u20131272","journal-title":"Headache"},{"key":"1622_CR6","unstructured":"Ubrelvy [package insert]: AbbVie; (2023). Accessed 24 July 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211765s007lbl.pdf"},{"key":"1622_CR7","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM et al (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381:2230\u20132241","journal-title":"N Engl J Med"},{"key":"1622_CR8","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A et al (2019) Effect of ubrogepant versus placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322:1887\u20131898","journal-title":"JAMA"},{"key":"1622_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/head.13682","volume":"60","author":"J Ailani","year":"2020","unstructured":"Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M et al (2020) Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache 60:141\u2013152","journal-title":"Headache"},{"key":"1622_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/head.13766","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S et al (2020) Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache 60:686\u2013700","journal-title":"Headache"},{"key":"1622_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-022-01419-7","volume":"23","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE et al (2022) Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain 23:50","journal-title":"J Headache Pain"},{"key":"1622_CR12","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s40120-022-00403-2","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Komori M, Tanji Y, Ozeki A, Sakai F (2022) Rapid onset and sustained efficacy of lasmiditan among Japanese patients with migraine: prespecified analyses of a randomized controlled trial. Neurol Ther 11:1721\u20131734","journal-title":"Neurol Ther"},{"key":"1622_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2006.08.010","volume":"28","author":"A Sunshine","year":"2006","unstructured":"Sunshine A, Mulhern SA, Olson N, Elkind A, Almas M, Sikes C (2006) Comparative sensitivity of stopwatch methodology and conventional pain assessment measures for detecting early response to triptans in migraine: results of a randomized, open-label pilot study. Clin Ther 28:1107\u20131115","journal-title":"Clin Ther"},{"key":"1622_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S0149-2918(02)80020-0","volume":"24","author":"P Black","year":"2002","unstructured":"Black P, Max MB, Desjardins P, Norwood T, Ardia A, Pallotta T (2002) A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain. Clin Ther 24:1072\u20131089","journal-title":"Clin Ther"},{"key":"1622_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Kolodner K, Bigal ME, Valade D, Lainez MJ, Pascual J et al (2009) Validity and reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia 29:751\u2013759","journal-title":"Cephalalgia"},{"key":"1622_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-021-01923-3","volume":"39","author":"AM Blumenfeld","year":"2022","unstructured":"Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H et al (2022) Ubrogepant is safe and efficacious in participants taking concomitant preventive medication for migraine: a pooled analysis of phase 3 trials. Adv Ther 39:692\u2013705","journal-title":"Adv Ther"},{"key":"1622_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-021-01260-4","volume":"22","author":"K Kollewe","year":"2021","unstructured":"Kollewe K, Gaul C, Gendolla A, Sommer K (2021) Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. J Headache Pain 22:50","journal-title":"J Headache Pain"},{"key":"1622_CR18","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/pm\/pnab093","volume":"22","author":"F Cohen","year":"2021","unstructured":"Cohen F, Armand C, Lipton RB, Vollbracht S (2021) Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med 22:1857\u20131863","journal-title":"Pain Med"},{"key":"1622_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther 10:809\u2013826","journal-title":"Pain Ther"},{"key":"1622_CR20","doi-asserted-by":"publisher","first-page":"788159","DOI":"10.3389\/fneur.2021.788159","volume":"12","author":"L Mechtler","year":"2021","unstructured":"Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM (2021) Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol 12:788159","journal-title":"Front Neurol"},{"key":"1622_CR21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","volume":"2","author":"A Singh","year":"2020","unstructured":"Singh A, Gupta D, Sahoo AK (2020) Acute migraine: can the new drugs clinically outpace? SN Compr Clin Med 2:1132\u20131138","journal-title":"SN Compr Clin Med"},{"key":"1622_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"RH Dworkin","year":"2005","unstructured":"Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP et al (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113:9\u201319","journal-title":"Pain"},{"key":"1622_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149\u2013158","journal-title":"Pain"},{"key":"1622_CR24","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS (2018) Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther 35:1763\u20131774","journal-title":"Adv Ther"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01622-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01622-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01622-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T18:02:41Z","timestamp":1700244161000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01622-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01622-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Respondents were required to provide written informed consent online. Participants were informed that their personal de-identified study-related data would be used in accordance with local privacy and data protection laws. The study protocol was approved by Advarra Institutional Review Board in the United States.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RBL has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie\/Allergan, Amgen, Biohaven, Dr. Reddy\u2019s Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff\u2019s Headache<\/i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock in Biohaven and Manistee.EE, NDA, and DS were employees of OPEN Health Group at the time of study conduct.LD serves as a consultant, advisory board member, or has received honoraria from AbbVie, Amgen, Eli Lilly, Novartis, and Teva.AMA, JC-DL, and KS are employees of AbbVie and may hold AbbVie stock.SH serves as a consultant, advisory board member, or has received honoraria from AbbVie, Amgen, Biohaven, Currax, Eli Lilly, Impel, Lundbeck, Novartis, Teva, Theranica, and Upsher-Smith.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}